Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib Trial
ReutersDec 17, 2025 9:08 PM
Dec 17 (Reuters) - Immuneering Corp IMRX.O:
IMMUNEERING ADVANCES TOWARDS DOSING FIRST PATIENT IN PHASE 3 ATEBIMETINIB TRIAL FOR FIRST-LINE METASTATIC PANCREATIC CANCER PATIENTS, SECURING ALIGNMENT WITH FDA AND EMA
IMMUNEERING EXPECTS TO DOSE FIRST PATIENT IN GLOBAL PHASE 3 REGISTRATIONAL TRIAL, MAPKEEPER 301, IN MID-2026
IMMUNEERING: EXPECTS TO SHARE TOPLINE RESULTS FROM TRIAL IN MID-2028
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Gold Price Hits New High: Has Bitcoin Fully Declined?
Gold prices surged over 70% in 2025, while Bitcoin fell over 5%. Will there be a chance for a comeback in the future?TradingKey
2 hours ago
US Q3 GDP Set for Release, Will US Stocks See a "Santa Claus Rally"?【The week ahead】
TradingKey - This week, global financial markets will enter "Christmas mode." Investors should focus on US GDP data, and Bank of Japan Governor Kazuo Ueda will deliver a speech, potentially offering clues on the interest rate trajectory for 2026.TradingKey
20 hours ago
Rocket Lab Stock Analysis: Why Is Rocket Lab Stock Price Soaring? Is Now a Good Time To Buy?
TradingKey - Even though Rocket Lab's stock price has seen substantial gains from its previous levels, we believe that Rocket Lab still offers speculative value.TradingKey
Mon, Dec 22
Elon Musk’s SpaceX Poised for Record-Breaking IPO: How Can Retail Investors Get In on the Action of Starlink Stock?
TradingKey - Elon Musk's rocket manufacturer SpaceX is expected to launch an IPO in 2026, with a target IPO valuation projected to reach $1.5 trillion. However, prior to its listing, the stock can only be traded in the private market, characterized by low information transparency and high capital baTradingKey
Fri, Dec 19
Tradingkey
